Annually 1 in 10 patients treated with direct oral anticoagulant (DOAC) requires a planned invasive procedure. Most of these procedures are associated with a low bleeding risk. In this setting, guidelines recommend not to perform the procedure at DOAC peak concentration ([DOAC]), which occurs 1 to 3 hours after intake. [...
Introduction: Direct oral anticoagulants (DOACs) are increasingly prescribed for prevention of throm...
Direct Oral Anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K...
SummaryDirect oral anticoagulants (DOAs) – inhibitors of thrombin or factor-Xa – are expected to rep...
Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for various indica...
Direct oral anticoagulants (DOAC) are used in several indications for the prevention and treatment o...
International audienceSince 2011, data on patients exposed to direct oral anticoagulants (DOAs) whil...
AIMS: Patients receiving direct oral anticoagulants (DOACs) frequently undergo elective invasive pro...
Since 2011, data on patients exposed to direct oral anticoagulants (DOAs) while undergoing invasive ...
Patients on direct oral anticoagulants (DOAC) may need interruption of treatment before surgery or i...
Patients on anticoagulant treatment are constantly increasing, with an estimated prevalence in Italy...
Patients on anticoagulant treatment are constantly increasing, with an estimated prevalence in Italy...
Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and provide ad...
The new oral direct anticoagulants (DOACs) could represent a new frontier for management of thromboe...
There is an increasing amount of literature on direct oral anticoagulant (DOAC) laboratory monitorin...
Direct oral anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K...
Introduction: Direct oral anticoagulants (DOACs) are increasingly prescribed for prevention of throm...
Direct Oral Anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K...
SummaryDirect oral anticoagulants (DOAs) – inhibitors of thrombin or factor-Xa – are expected to rep...
Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for various indica...
Direct oral anticoagulants (DOAC) are used in several indications for the prevention and treatment o...
International audienceSince 2011, data on patients exposed to direct oral anticoagulants (DOAs) whil...
AIMS: Patients receiving direct oral anticoagulants (DOACs) frequently undergo elective invasive pro...
Since 2011, data on patients exposed to direct oral anticoagulants (DOAs) while undergoing invasive ...
Patients on direct oral anticoagulants (DOAC) may need interruption of treatment before surgery or i...
Patients on anticoagulant treatment are constantly increasing, with an estimated prevalence in Italy...
Patients on anticoagulant treatment are constantly increasing, with an estimated prevalence in Italy...
Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and provide ad...
The new oral direct anticoagulants (DOACs) could represent a new frontier for management of thromboe...
There is an increasing amount of literature on direct oral anticoagulant (DOAC) laboratory monitorin...
Direct oral anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K...
Introduction: Direct oral anticoagulants (DOACs) are increasingly prescribed for prevention of throm...
Direct Oral Anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K...
SummaryDirect oral anticoagulants (DOAs) – inhibitors of thrombin or factor-Xa – are expected to rep...